BioCentury | Oct 22, 2012
Clinical News

Iprivask: Phase IV data

...are needed, but said it does not have plans for additional trials at this time. Canyon Pharmaceuticals AG...
BioCentury | Dec 5, 2011
Company News

Basilea infectious, dermatology news

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Nov 30, 2011
Company News

Basilea bolsters board

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 31, 2011
Company News

Basilea infectious, dermatology news

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); and Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 10, 2011
Finance

Brawnier for deals

...plc (LSE:GSK; NYSE:GSK), would add expertise in commercial strategy, while Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 10, 2011
Company News

Basilea infectious, dermatology news

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 7, 2011
Company News

HBM seeks expanded Basilea board

...former managing director and SVP of GlaxoSmithKline Germany; Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | May 9, 2011
Clinical News

Desirudin cardiovascular data

...DVT in patients undergoing hip replacement surgery and as Revasc in Europe for DVT prophylaxis. Canyon Pharmaceuticals AG...
BioCentury | Apr 26, 2010
Clinical News

Iprivask desirudin: Phase IIIb data

...an anticoagulant to prevent or treat thrombosis in patients with or at risk for HIT. Canyon Pharmaceuticals AG...
BioCentury | Mar 8, 2010
Company News

Canyon Pharmaceuticals sales and marketing update

...patients in clinical trials used an average of two vials per day for nine days. Canyon Pharmaceuticals...
Items per page:
1 - 10 of 10
BioCentury | Oct 22, 2012
Clinical News

Iprivask: Phase IV data

...are needed, but said it does not have plans for additional trials at this time. Canyon Pharmaceuticals AG...
BioCentury | Dec 5, 2011
Company News

Basilea infectious, dermatology news

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Nov 30, 2011
Company News

Basilea bolsters board

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 31, 2011
Company News

Basilea infectious, dermatology news

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); and Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 10, 2011
Finance

Brawnier for deals

...plc (LSE:GSK; NYSE:GSK), would add expertise in commercial strategy, while Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 10, 2011
Company News

Basilea infectious, dermatology news

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | Oct 7, 2011
Company News

HBM seeks expanded Basilea board

...former managing director and SVP of GlaxoSmithKline Germany; Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...
BioCentury | May 9, 2011
Clinical News

Desirudin cardiovascular data

...DVT in patients undergoing hip replacement surgery and as Revasc in Europe for DVT prophylaxis. Canyon Pharmaceuticals AG...
BioCentury | Apr 26, 2010
Clinical News

Iprivask desirudin: Phase IIIb data

...an anticoagulant to prevent or treat thrombosis in patients with or at risk for HIT. Canyon Pharmaceuticals AG...
BioCentury | Mar 8, 2010
Company News

Canyon Pharmaceuticals sales and marketing update

...patients in clinical trials used an average of two vials per day for nine days. Canyon Pharmaceuticals...
Items per page:
1 - 10 of 10